Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777647 | 0.92 | DDB1 (0.36) | DDB1CRBNLMNAMEN1KMT2A | |
| SCHEMBL4777868 | 0.85 | DDB1 (0.36) | DDB1CRBN | |
| SCHEMBL10054111 | 0.83 | DDB1 (0.35) | DDB1CRBN | |
| SCHEMBL4776620 | 0.80 | CRBN (0.37) | DDB1CRBN | |
| SCHEMBL4780692 | 0.79 | DDB1 (0.32) | DDB1CRBNALDH1A1MAPT | |
| SCHEMBL4779917 | 0.76 | CYP2C19 (0.40) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4776701 | 0.76 | DDB1 (0.38) | DDB1CRBNLMNAALDH1A1MAPK1 | |
| SCHEMBL10054602 | 0.74 | DDB1 (0.37) | DDB1CRBNLMNAALDH1A1MEN1 | |
| SCHEMBL4778654 | 0.72 | DDB1 (0.38) | DDB1CRBNLMNAALDH1A1KMT2A | |
| SCHEMBL27433651 | 0.71 | DDB1 (0.41) | DDB1CRBNALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524742-B2 | Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-09-03 | — | — | US | disclosed |
| US-8524742-B2 | Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-09-03 | — | — | US | disclosed |
| EP-1964842-B1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | TIAN JIN HEMAY BIO TECH CO LTD (CN) | 2012-09-12 | — | — | EP | disclosed |
| EP-1964842-B1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | TIAN JIN HEMAY BIO TECH CO LTD (CN) | 2012-09-12 | — | — | EP | disclosed |
| US-20120220631-A1 | USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-8183260-B2 | small molecule, low toxicity, high efficiency, high economic value; 5-(2,6-dioxopiperidin-3-yl)-5H-thieno(3,4-c)pyrrole-4,6-dione: | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2012-05-22 | — | — | US | disclosed |
| US-8183260-B2 | small molecule, low toxicity, high efficiency, high economic value; 5-(2,6-dioxopiperidin-3-yl)-5H-thieno(3,4-c)pyrrole-4,6-dione: | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2012-05-22 | — | — | US | disclosed |
| EP-1964842-A1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964842-A1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2008-09-03 | — | — | EP | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220631-A1 | USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR | TNF, TPMT, TNFRSF1A | DDB1 790/4885CRBN 1305/4885LMNA 4103/4885 |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, CD40 | DDB1 1951/4885CRBN 938/4885LMNA 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.